NCT03928535 (COPD) is a NA clinical trial of High-FlowNasal Cannula in High-Flow Nasal Cannula, sponsored by Xiangya Hospital of Central South University.

Who is sponsoring NCT03928535?

NCT03928535 is sponsored by Xiangya Hospital of Central South University.

What drugs are being tested in NCT03928535?

Interventions in NCT03928535: High-FlowNasal Cannula, Noninvasive Ventilation.

What condition does NCT03928535 study?

NCT03928535 studies High-Flow Nasal Cannula, COPD.

Is NCT03928535 still recruiting?

NCT03928535 is currently status unknown. Last updated 26 April 2019.

Last reviewed 2019-04-26 · How we verify

NCT03928535: COPD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation in Patients With Hypercapnic COPD

Status unknown NA Last updated 26 April 2019

What this trial tests

NA trial testing High-FlowNasal Cannula in High-Flow Nasal Cannula in 100 participants. Status unknown.

Timeline

1 May 2016

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Xiangya Hospital of Central South University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	1 May 2016
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across China

Drugs / interventions tested

High-FlowNasal Cannula
Noninvasive Ventilation

Conditions studied

High-Flow Nasal Cannula — all drugs for High-Flow Nasal Cannula →
COPD — all drugs for COPD →

Sponsor

Xiangya Hospital of Central South University

Who can join

Eligibility, any sex, with High-Flow Nasal Cannula or COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To test if high-flow conditioned oxygen therapy is noninferior to NIV for preventing postextubation respiratory failure and reintubation in patients with hypercapnic COPD, investigators plan to conduct the participants level, 1:1 randomized trial at the respiratory ICU. Participants were randomized to undergo either high-flow conditioned oxygen therapy or noninvasive mechanical ventilation after extubation. Primary outcomes were reintubation and postextubation respiratory failure within 72 hours. Secondary outcomes included length of RICU stay after extubation and mortality; partial pressure of arterial carbon dioxide.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

High-flow nasal cannulae for respiratory support in adult intensive care patients.
Corley A, Rickard CM, Aitken LM, Johnston A, et al · · 2017 · cited 44× · PMID 28555461 · DOI 10.1002/14651858.cd010172.pub2
High-flow nasal cannulae for respiratory support in adult intensive care patients.
Lewis SR, Baker PE, Parker R, Smith AF. · · 2021 · cited 43× · PMID 33661521 · DOI 10.1002/14651858.cd010172.pub3

Verify or expand the search:

Other Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03928535 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
Last refreshed: 26 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03928535.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing